Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case Series
- Author:
Hyeon Gyu KANG
1
;
Jiwon KOH
;
Tae Min KIM
;
Doo Hee HAN
;
Tae-Bin WON
;
Dong-Wan KIM
;
Dong-Young KIM
;
Bhumsuk KEAM
Author Information
- Publication Type:Case Report
- From:Cancer Research and Treatment 2024;56(3):967-971
- CountryRepublic of Korea
- Language:English
- Abstract: SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor has aggressive nature with a poor prognosis. Patients with this disease were diagnosed by immunohistochemistry or next-generation sequencing. Those who were able to receive a surgery tended to be cured, while the others treated with chemotherapy, radiation therapy, or immune checkpoint inhibitor were often insensitive to these therapies. However, one having CD274 (PD-L1) amplification showed the response to immune checkpoint inhibitor and a good prognosis. We believed that this report could provide promising information for determining the optimal treatment option.
